Many healthcare entities have explored certain alternative risk transfer arrangements as a means for insuring, or perhaps self-insuring, various exposures. The use of captive insurance arrangements has been a common approach, and thus, "protected cell companies" have become popular vehicles.
Most protected cell companies involve a commercial insurer that sponsors a captive insurance company. That captive has several segregated cells which are funded by business insureds to cover their own risks. These arrangements are often used by small- to mid-sized businesses that do not have the expertise or resources to establish their own captive insurance company.
The IRS has published a new Revenue Ruling (2008-8), which provides guidance with respect to tax issues pertaining to protected cell companies. Protected cell companies are insurance companies, often formed offshore, which have multiple separate cells, each of which are insulated from the credit risks of the other cells. In effect, they have multiple companies operating within a single corporate entity.
CONSISTENT VIEW
The IRS has taken a consistent view over the years that more than one insured must be involved in order for the elements of risk shifting and risk distribution to be present. For example, a captive insurance company owned by, and insuring the risks of, a single parent does not satisfy the risk shifting and distribution requirements. The new Revenue Ruling continues to follow this position, but has not answered the key question of how many insureds are enough.
In following its prior precedent, the IRS concluded that an arrangement whereby the cell provided liability coverage to its sole shareholder, and no others, did not involve risk-shifting and distribution. Thus, the arrangement did not constitute an insurance contract, and the sole shareholder was not allowed to deduct the premiums it paid to the cell.
On the other hand, if a cell is used to insure the risks of multiple affiliated entities, then the premiums paid by the affiliates would be considered insurance premiums and would be tax-deductible. The IRS concluded in that situation that risk-shifting had occurred among the affiliated entities.
The Revenue Ruling settles the question of whether the mere existence of multiple cells within the protected cell company changes the historical analysis of whether an insurance contract exists. It does not-risk shifting and distribution must still be present. While the Revenue Ruling is important in that it provides clarification on this point, it should not come as a surprise to most corporate taxpayers.
This column is written for informational purposes only and should not be construed as legal advice.
Barry Senterfitt is a partner in the insurance industry practice of Akin Gump Strauss Hauer & Feld LLP in the firm's Austin, Texas, office.
Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care
April 18th 2024Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen